Details of the Drug Combinations

General Information of This Drug (ID: DMCXRZF)

Drug Name

LY2603618 DMCXRZF

Synonyms

LY2603618; Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618 IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
LY2603618 + Ruxolitinib	DCZ29US	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[2]
LY2603618 + Panobinostat	DCCBJ0O	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Gemcitabine + LY2603618	DCMELAV	Gemcitabine	Pancreatic Neoplasms	[3]
Gemcitabine + LY2603618	DCJIJ1U	Gemcitabine	Cancer	[4]
Gemcitabine + LY2603618	DCW2ZVG	Gemcitabine	Advanced Cancer	[5]
LY2603618 + Pemetrexed	DC03405	Pemetrexed	Non Small Cell Lung Cancer	[6]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7960).
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	ClinicalTrials.gov (NCT00839332) A Study for Participants With Pancreatic Cancer
4	ClinicalTrials.gov (NCT01358968) A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
5	ClinicalTrials.gov (NCT01296568) C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
6	ClinicalTrials.gov (NCT00988858) A Study of Advanced or Metastatic Non-small Cell Lung Cancer